Lates News

Silence Therapeutics (SLN.US): The 2025 Q3 financial report achieved revenue of $159,000, down from $1.498 million, with an expected value of $4.41362 million; earnings per share were -$0.15, down from -$0.25, with an expected value of -$0.28.